The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI -
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
Securing the Future of Open Source Software
Jack Cable and Remy DeCausemaker explore how CISA and CMS are tackling open source software (OSS) security in government.
4m listen -
How AI Will Continue to Advance Biometric Tech
At Identity Week, Arun Vemury discussed how error rates in facial recognition have dropped over the past decade thanks to machine learning.
12m listen -
TSA is Innovating Digital Identity Solutions with AI
At Identity Week, Jason Lim talked about the ways that digital identity is changing the way people travel securely.
10m listen -
The Security and UX Standards That Power Digital Identity Programs
Live from Identity Week, Ryan Galluzzo discusses the latest draft of NIST's Digital Identity Guidelines for the identity-proofing process.
18m listen
